arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Vanda Pharmaceuticals Inc.

VNDA
$3.60 ▼ -0.28 (-7.35%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vanda Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $217.7M
Dividend Yield —
Revenue Growth 24.1% ↗
Op. Margin -33.7% ↗
ROIC -11.9% ↗
FCF / Share $-0.48 ↗
Trailing P/E —
Price / Book 1.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$69.81M
↑ +24.1% —
Net Income Profit after all expenses
$-48.57M
↓ -64.7% —
Operating Margin Operating profit as % of sales
-33.7%
↑ +73.3% 4th
FCF / Share Free cash flow per share
$-0.48
↑ +8.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
13
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 69 quarters